| Recruiting | Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma NCT07388563 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma NCT07356245 | Jonathan Brammer | Phase 2 |
| Not Yet Recruiting | CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation NCT07117305 | Zhengzhou University | Phase 1 / Phase 2 |
| Recruiting | Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL NCT07106723 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblasti NCT06390319 | St. Jude Children's Research Hospital | Phase 2 |
| Recruiting | A Study of Enasidenib in People With T-Cell Lymphoma NCT06756308 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma NCT05996185 | Yale University | Phase 2 |
| Terminated | Study of Tazemetostat in Lymphoid Malignancies NCT05983965 | University of Alabama at Birmingham | Phase 1 |
| Completed | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignanc NCT06492304 | CRISPR Therapeutics | Phase 1 / Phase 2 |
| Recruiting | Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing NCT06550427 | National Taiwan University Hospital | — |
| Recruiting | Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymp NCT06420076 | Essen Biotech | Phase 1 / Phase 2 |
| Unknown | Mitochondrial dysfUnction: a Key Player in Doxorubicin-induced Skeletal and Cardiac muscLE Damage NCT05731375 | UMC Utrecht | — |
| Completed | A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab Vedotin NCT05886478 | Takeda | — |
| Recruiting | Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma NCT04234048 | SciTech Development, Inc. | Phase 1 |
| Recruiting | Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T NCT06224049 | BGI, China | EARLY_Phase 1 |
| Recruiting | Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution NCT06131801 | Children's Hospital Medical Center, Cincinnati | — |
| Completed | A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R NCT05665530 | Prelude Therapeutics | Phase 1 |
| Recruiting | A Registry for People With T-cell Lymphoma NCT05978141 | Memorial Sloan Kettering Cancer Center | — |
| Recruiting | Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma NCT05313243 | Yale University | Phase 2 |
| Unknown | Chidamide Combined With Azacitidine and Mitoxantrone Liposome in the Treatment of Relapsed/Refractory (nTFHL) NCT05772728 | The First Affiliated Hospital with Nanjing Medical University | N/A |
| Unknown | A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma NCT05852028 | Ruijin Hospital | — |
| Completed | A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma NCT05442554 | Takeda | Phase 4 |
| Recruiting | Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS) NCT05230680 | Won Seog Kim | Phase 1 / Phase 2 |
| Unknown | Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-c NCT05367856 | Ruijin Hospital | Phase 2 |
| Unknown | Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymp NCT05387226 | The First Affiliated Hospital of Bengbu Medical University | Phase 1 |
| Completed | Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Of NCT06782854 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Recruiting | Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma NCT05075460 | Peking Union Medical College Hospital | Phase 3 |
| Completed | Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphoma NCT04840875 | Beijing Boren Hospital | Phase 1 |
| Unknown | Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T NCT04712864 | Legend Biotech USA Inc | Phase 1 |
| Terminated | LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor NCT04973527 | Beijing Boren Hospital | Phase 1 |
| Unknown | Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies NCT04264078 | Xinqiao Hospital of Chongqing | EARLY_Phase 1 |
| Recruiting | BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D2 NCT04752826 | BioInvent International AB | Phase 1 / Phase 2 |
| Unknown | CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. NCT04653649 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Phase 1 / Phase 2 |
| Terminated | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies NCT04502446 | CRISPR Therapeutics AG | Phase 1 |
| Active Not Recruiting | Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas NCT04331119 | Washington University School of Medicine | Phase 2 |
| Recruiting | CD4CAR for CD4+ Leukemia and Lymphoma NCT03829540 | Huda Salman | Phase 1 |
| Withdrawn | Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation An NCT04334174 | University of Kansas Medical Center | Phase 2 |
| Active Not Recruiting | A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma NCT03952078 | Corvus Pharmaceuticals, Inc. | Phase 1 |
| Completed | Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia ( NCT03792256 | Children's Oncology Group | Phase 1 |
| Completed | Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory NCT03770000 | Rhizen Pharmaceuticals SA | Phase 1 / Phase 2 |
| Unknown | Allo-HSCT as First-line Consolidation in High-risk PTCL NCT03672084 | Peking University People's Hospital | — |
| Completed | Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoi NCT03734601 | Stanford University | Phase 2 |
| Enrolling By Invitation | Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells NCT03628612 | Autolus Limited | Phase 2 |
| Completed | p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid NCT02846935 | Yogen Saunthararajah | EARLY_Phase 1 |
| Unknown | Pembrolizumab for T/NK-cell lymphomasNK-cell Lymphomas NCT03021057 | The University of Hong Kong | Phase 2 |
| Completed | A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymp NCT02588651 | Deepa Jagadeesh | Phase 2 |
| Completed | Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma NCT02424045 | Samsung Medical Center | Phase 2 |
| Completed | Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma NCT02309580 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Unknown | T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients NCT03207789 | Grupo de Estudos Multicentricos em Onco-Hematologia | — |
| Completed | Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatme NCT01902225 | Weiyun Ai | Phase 1 |
| Terminated | A Phase II Study of Doxycycline in Relapsed NHL NCT02086591 | University of Rochester | Phase 2 |
| Completed | Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies NCT02017613 | Rhizen Pharmaceuticals SA | Phase 1 |
| Completed | High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant NCT01941680 | University Hospital Center of Martinique | — |
| Terminated | A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma NCT01878708 | Dana-Farber Cancer Institute | EARLY_Phase 1 |
| Completed | Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies NCT01871675 | SCRI Development Innovations, LLC | Phase 1 |
| Completed | ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients NCT01777152 | Seagen Inc. | Phase 3 |
| Unknown | Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma NCT01854112 | Far Eastern Memorial Hospital | — |
| Completed | Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) NCT01553786 | The Lymphoma Academic Research Organisation | Phase 2 |
| Unknown | Trial of Endostar Combined With CHOPT for T Cell Lymphoma NCT01430013 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Completed | AMG 319 Lymphoid Malignancy FIH NCT01300026 | Amgen | Phase 1 |
| Completed | Tandem Auto-Allo Transplant for Lymphoma NCT01181271 | Massachusetts General Hospital | Phase 2 |
| Completed | A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients NCT01561833 | Yale University | Phase 1 |
| Completed | Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma NCT00959686 | French Innovative Leukemia Organisation | Phase 2 |
| Unknown | Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma NCT00974324 | Fudan University | Phase 2 |
| Terminated | Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma NCT00880867 | Nevada Cancer Institute | Phase 1 |
| Completed | Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma NCT00798096 | Rigel Pharmaceuticals | Phase 2 |
| Completed | A Study for Patients With Non-Hodgkin's Lymphomas NCT00542919 | Eli Lilly and Company | Phase 2 |
| Terminated | CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma NCT00893516 | Emergent BioSolutions | Phase 2 |
| Completed | A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma NCT00322985 | AHS Cancer Control Alberta | Phase 2 |
| Completed | HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma NCT00877656 | Emergent BioSolutions | Phase 2 / Phase 3 |
| Terminated | LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma NCT00161239 | University of Medicine and Dentistry of New Jersey | N/A |
| Completed | Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma NCT00161590 | Weill Medical College of Cornell University | Phase 1 |
| Completed | Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System NCT00001582 | National Cancer Institute (NCI) | — |